G1’s Cosela Could Show Promise In Triple-Negative Breast Cancer Despite Colorectal Cancer Fail
Shares Down 51%
The US biotech’s myeloprotective drug saw worse responses in a late-stage colorectal cancer trial when compared with placebo but some analysts say other label expansion efforts could fare better.
